Scarica l'app Stockscreener
1.76
1.12%
-0.02
Dopo l'orario di chiusura:
1.76
Precedente Chiudi:
$1.78
Aprire:
$1.87
Volume 24 ore:
4,956
Relative Volume:
0.51
Capitalizzazione di mercato:
$54.98M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-0.6985
EPS:
-2.5197
Flusso di cassa netto:
-
1 W Prestazione:
+5.04%
1M Prestazione:
+17.33%
6M Prestazione:
-20.00%
1 anno Prestazione:
-37.14%
Intervallo 1D:
$1.72
$1.87
Intervallo di 1 settimana:
$1.67
$1.87
Portata 52W:
$1.10
$3.89
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Nome
Adlai Nortye Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ANL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.76 | 65.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Borsa (ANL) Ultime notizie
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 News Drivers & AI Powered Market Entry Ideas - Newser
Live market analysis of SPAIJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Key resistance and support levels for Adlai Nortye Ltd. Depositary ReceiptJuly 2025 Final Week & Fast Gain Stock Tips - Newser
Candlestick signals on FBGL stock todayForecast Cut & Stock Market Timing Techniques - Newser
F.N.B. Corporation stock trendline breakdownJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - Newser
Is Brookfield Asset Management Ltd. stock reversal real or fake2025 Price Action Summary & Reliable Price Breakout Alerts - Newser
How to use a screener to detect IROHW breakouts2025 Risk Factors & Expert Curated Trade Setups - Newser
Analyzing drawdowns of Coeptis Therapeutics Holdings Inc. with statistical toolsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Is GSK plc ADRhedged forming a bottoming base2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Trend analysis for Intercontinental Exchange Inc. this weekWeekly Risk Report & Reliable Intraday Trade Alerts - Newser
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Long term hold vs stop loss in CEADJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Adlai Nortye (NASDAQ:ANL) Stock Price Up 3.2% – Should You Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
AlphaTime Acquisition Corp Debt Equity Composite Units recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
Comparing Adlai Nortye Ltd. Depositary Receipt in custom built stock radarsDaily Upside Movement Prediction With Data - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Adlai Nortye Ltd. Announces 2025 Share Incentive Plan and Board Changes - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened - Defense World
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Adlai Nortye to present at AACR Annual Meeting with two abstracts scheduled. - AInvest
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com India
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
Adlai Nortye Announces 2.5M ADS IPO at $23/sh - Investing.com
CRVO Stock Quote Price and Forecast - CNN
Adlai Nortye Ltd Adr Azioni (ANL) Dati Finanziari
Non sono disponibili dati finanziari per Adlai Nortye Ltd Adr (ANL). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):